Pumecitinib
CAS No. 2401057-12-1
Pumecitinib( —— )
Catalog No. M35964 CAS No. 2401057-12-1
Pumecitinib is a Janus kinase (JAK) inhibitor. Pumecitinib exhibits anti-inflammatory activity.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 50 | In Stock |
|
| 5MG | 42 | In Stock |
|
| 10MG | 67 | In Stock |
|
| 25MG | 124 | In Stock |
|
| 50MG | 193 | In Stock |
|
| 100MG | 275 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NamePumecitinib
-
NoteResearch use only, not for human use.
-
Brief DescriptionPumecitinib is a Janus kinase (JAK) inhibitor. Pumecitinib exhibits anti-inflammatory activity.
-
DescriptionPumecitinib is a Janus kinase (JAK) inhibitor with anti-inflammatory activity.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayAngiogenesis
-
TargetJAK
-
RecptorJAK
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number2401057-12-1
-
Formula Weight400.46
-
Molecular FormulaC17H20N8O2S
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 125 mg/mL (312.14 mM; Ultrasonic (<60°C)
-
SMILESCC(C)S(=O)(=O)N1CC(CC#N)(C1)n1cc(c(N)n1)-c1ncnc2[nH]ccc12
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. WHO Drug Information-World Health Organization (WHO).
molnova catalog
related products
-
JAK2-IN-6
JAK2-IN-6, a polysubstituted aminothiazole derivative, is a potent and selective inhibitor of JAK2 (ic50 at 22.86 μg/mL).
-
PF-956980
A potent, highly specific JAK3 inhibitor with IC50 of 4 nM; shows only modest inhibition of PKA (6.7 uM) and LCK (10.9 uM) in vitro.
-
BMS-986165
BMS-986165 is differentiated from previous JAK inhibitors due its unique ability to selectively bind to the pseudokinase (JH2) domain of TYK2 and inhibit its function through an allosteric mechanism.
Cart
sales@molnova.com